Breaking the Barrier to an HIV Vaccine

打破艾滋病毒疫苗的障碍

• 批准号: 10487962
• 负责人: Sara Sawyer
• 金额: $ 109.55万
• 依托单位: UNIVERSITY OF COLORADO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10487962
• 关键词: AIDS/HIV problem; Animal Model; Consequentialism; Development; HIV; HIV Infections; HIV vaccine; HIV-1; Human body; Immune; Macaca; Modeling; Monkeys; Persons; Pharmaceutical Preparations; Primates; System; Testing; Vaccines; Viral reservoir; Virus Latency; acute infection; cross immunity; pandemic disease; tool; vaccine candidate; vaccine development; viral transmission

PROJECT SUMMARY HIV remains the most consequential zoonosis of the last century, with 36 million fatalities and another 37 million infected. Even today, almost 2,000 people per day die of HIV/AIDS globally. Medications are reducing the effects of HIV on the human body and transmission of the virus to others. However, 40 years into the pandemic, there are no vaccines. Effective HIV vaccines remain our only hope of ending the HIV/AIDS pandemic once and for all. HIV vaccines are mostly developed in macaque monkeys, although this primate model of HIV infection has many limitations. Here, we explore a new animal model for HIV infection that recapitulates all key milestones in HIV acute infection and in the establishment of the latent viral reservoir. We develop the tools necessary to turn this into the long-sought model for HIV vaccine development. This new animal model will provide the perfect system to study the immune correlates of protection, the breadth of cross-protection against different HIV-1 subtypes, and to test and develop vaccine candidates.

项目摘要 艾滋病毒仍然是上个世纪最结果的人畜共患病，死亡人数为3600万，还有3700万 已感染。即使在今天，全球每天近2,000人死于艾滋病毒/艾滋病。药物正在减少影响 艾滋病毒在人体上的艾滋病毒和病毒传播给他人。但是，大流行40年 不是疫苗。有效的艾滋病毒疫苗仍然是我们唯一结束艾滋病毒/艾滋病大流行的希望 全部。 HIV疫苗主要是在猕猴中开发的，尽管这种灵长类动物的HIV感染模型具有 许多局限性。在这里，我们探索了一种用于HIV感染的新动物模型，该模型概括了所有关键里程碑 艾滋病毒急性感染和建立潜在病毒储存剂。我们开发了转弯所需的工具 这是艾滋病毒疫苗开发的长期追求的模型。这种新动物模型将提供完美 研究保护免疫相关的系统，跨保护的广度 亚型，并测试和开发候选疫苗。